Karin Herbschleb Selected Research

BAY 1238097

1/2019

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Herbschleb Research Topics

Disease

2	Neoplasms (Cancer) 01/2019 - 12/2018
1	Osteosarcoma (Osteogenic Sarcoma) 06/2022
1	Melanoma (Melanoma, Malignant) 11/2019
1	Adenocarcinoma 12/2018
1	Breast Neoplasms (Breast Cancer) 12/2018
1	Neoplasm Metastasis (Metastasis) 12/2018
1	Colorectal Neoplasms (Colorectal Cancer) 12/2018

Drug/Important Bio-Agent (IBA)

1	mifamurtideIBA 06/2022
1	Biomarkers (Surrogate Marker)IBA 06/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2019
1	BAY 1238097IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	SirtuinsIBA 12/2018
1	Yttrium-90IBA 12/2018

Therapy/Procedure

3	Therapeutics 06/2022 - 12/2018
1	Drug Therapy (Chemotherapy) 12/2018
1	Microspheres (Microsphere) 12/2018
1	Radiotherapy 12/2018